274 related articles for article (PubMed ID: 25343991)
1. LRRK2 overexpression alters glutamatergic presynaptic plasticity, striatal dopamine tone, postsynaptic signal transduction, motor activity and memory.
Beccano-Kelly DA; Volta M; Munsie LN; Paschall SA; Tatarnikov I; Co K; Chou P; Cao LP; Bergeron S; Mitchell E; Han H; Melrose HL; Tapia L; Raymond LA; Farrer MJ; Milnerwood AJ
Hum Mol Genet; 2015 Mar; 24(5):1336-49. PubMed ID: 25343991
[TBL] [Abstract][Full Text] [Related]
2. Behavioral deficits and striatal DA signaling in LRRK2 p.G2019S transgenic rats: a multimodal investigation including PET neuroimaging.
Walker MD; Volta M; Cataldi S; Dinelle K; Beccano-Kelly D; Munsie L; Kornelsen R; Mah C; Chou P; Co K; Khinda J; Mroczek M; Bergeron S; Yu K; Cao LP; Funk N; Ott T; Galter D; Riess O; Biskup S; Milnerwood AJ; Stoessl AJ; Farrer MJ; Sossi V
J Parkinsons Dis; 2014; 4(3):483-98. PubMed ID: 25000966
[TBL] [Abstract][Full Text] [Related]
3. Dopamine D2 receptor activation potently inhibits striatal glutamatergic transmission in a G2019S LRRK2 genetic model of Parkinson's disease.
Tozzi A; Durante V; Bastioli G; Mazzocchetti P; Novello S; Mechelli A; Morari M; Costa C; Mancini A; Di Filippo M; Calabresi P
Neurobiol Dis; 2018 Oct; 118():1-8. PubMed ID: 29908325
[TBL] [Abstract][Full Text] [Related]
4. Chronic and acute LRRK2 silencing has no long-term behavioral effects, whereas wild-type and mutant LRRK2 overexpression induce motor and cognitive deficits and altered regulation of dopamine release.
Volta M; Cataldi S; Beccano-Kelly D; Munsie L; Tatarnikov I; Chou P; Bergeron S; Mitchell E; Lim R; Khinda J; Lloret A; Bennett CF; Paradiso C; Morari M; Farrer MJ; Milnerwood AJ
Parkinsonism Relat Disord; 2015 Oct; 21(10):1156-63. PubMed ID: 26282470
[TBL] [Abstract][Full Text] [Related]
5. Altered Development of Synapse Structure and Function in Striatum Caused by Parkinson's Disease-Linked LRRK2-G2019S Mutation.
Matikainen-Ankney BA; Kezunovic N; Mesias RE; Tian Y; Williams FM; Huntley GW; Benson DL
J Neurosci; 2016 Jul; 36(27):7128-41. PubMed ID: 27383589
[TBL] [Abstract][Full Text] [Related]
6. Synaptic dysfunction in Parkinson's disease.
Picconi B; Piccoli G; Calabresi P
Adv Exp Med Biol; 2012; 970():553-72. PubMed ID: 22351072
[TBL] [Abstract][Full Text] [Related]
7. Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S.
Li X; Patel JC; Wang J; Avshalumov MV; Nicholson C; Buxbaum JD; Elder GA; Rice ME; Yue Z
J Neurosci; 2010 Feb; 30(5):1788-97. PubMed ID: 20130188
[TBL] [Abstract][Full Text] [Related]
8. Parkinson's Disease-Linked LRRK2-G2019S Mutation Alters Synaptic Plasticity and Promotes Resilience to Chronic Social Stress in Young Adulthood.
Matikainen-Ankney BA; Kezunovic N; Menard C; Flanigan ME; Zhong Y; Russo SJ; Benson DL; Huntley GW
J Neurosci; 2018 Nov; 38(45):9700-9711. PubMed ID: 30249796
[TBL] [Abstract][Full Text] [Related]
9. (G2019S) LRRK2 causes early-phase dysfunction of SNpc dopaminergic neurons and impairment of corticostriatal long-term depression in the PD transgenic mouse.
Chou JS; Chen CY; Chen YL; Weng YH; Yeh TH; Lu CS; Chang YM; Wang HL
Neurobiol Dis; 2014 Aug; 68():190-9. PubMed ID: 24830390
[TBL] [Abstract][Full Text] [Related]
10. The Parkinson's Disease-Associated Mutation LRRK2-G2019S Impairs Synaptic Plasticity in Mouse Hippocampus.
Sweet ES; Saunier-Rebori B; Yue Z; Blitzer RD
J Neurosci; 2015 Aug; 35(32):11190-5. PubMed ID: 26269629
[TBL] [Abstract][Full Text] [Related]
11. Pathway-specific dysregulation of striatal excitatory synapses by LRRK2 mutations.
Chen C; Soto G; Dumrongprechachan V; Bannon N; Kang S; Kozorovitskiy Y; Parisiadou L
Elife; 2020 Oct; 9():. PubMed ID: 33006315
[TBL] [Abstract][Full Text] [Related]
12. Dopamine D2 receptor-mediated neuroprotection in a G2019S Lrrk2 genetic model of Parkinson's disease.
Tozzi A; Tantucci M; Marchi S; Mazzocchetti P; Morari M; Pinton P; Mancini A; Calabresi P
Cell Death Dis; 2018 Feb; 9(2):204. PubMed ID: 29434188
[TBL] [Abstract][Full Text] [Related]
13. Lack of exacerbation of neurodegeneration in a double transgenic mouse model of mutant LRRK2 and tau.
Mikhail F; Calingasan N; Parolari L; Subramanian A; Yang L; Flint Beal M
Hum Mol Genet; 2015 Jun; 24(12):3545-56. PubMed ID: 25804954
[TBL] [Abstract][Full Text] [Related]
14. Lrrk2 and alpha-synuclein are co-regulated in rodent striatum.
Westerlund M; Ran C; Borgkvist A; Sterky FH; Lindqvist E; Lundströmer K; Pernold K; Brené S; Kallunki P; Fisone G; Olson L; Galter D
Mol Cell Neurosci; 2008 Dec; 39(4):586-91. PubMed ID: 18790059
[TBL] [Abstract][Full Text] [Related]
15. R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice.
Tong Y; Pisani A; Martella G; Karouani M; Yamaguchi H; Pothos EN; Shen J
Proc Natl Acad Sci U S A; 2009 Aug; 106(34):14622-7. PubMed ID: 19667187
[TBL] [Abstract][Full Text] [Related]
16. Increased glutamate transmission onto dorsal striatum spiny projection neurons in Pink1 knockout rats.
Creed RB; Roberts RC; Farmer CB; McMahon LL; Goldberg MS
Neurobiol Dis; 2021 Mar; 150():105246. PubMed ID: 33387634
[TBL] [Abstract][Full Text] [Related]
17. Role of LRRK2 in the regulation of dopamine receptor trafficking.
Rassu M; Del Giudice MG; Sanna S; Taymans JM; Morari M; Brugnoli A; Frassineti M; Masala A; Esposito S; Galioto M; Valle C; Carri MT; Biosa A; Greggio E; Crosio C; Iaccarino C
PLoS One; 2017; 12(6):e0179082. PubMed ID: 28582422
[TBL] [Abstract][Full Text] [Related]
18. In vivo overexpression of synaptogyrin-3 promotes striatal synaptic dopamine uptake in LRRK2
Ho PW; Li L; Liu HF; Choi ZY; Chang EES; Pang SY; Malki Y; Leung CT; Kung MH; Ramsden DB; Ho SL
Brain Behav; 2023 Feb; 13(2):e2886. PubMed ID: 36624932
[TBL] [Abstract][Full Text] [Related]
19. Mouse models for LRRK2 Parkinson's disease.
Xu Q; Shenoy S; Li C
Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S186-9. PubMed ID: 22166430
[TBL] [Abstract][Full Text] [Related]
20. Microarray expression analysis in idiopathic and LRRK2-associated Parkinson's disease.
Botta-Orfila T; Tolosa E; Gelpi E; Sànchez-Pla A; Martí MJ; Valldeoriola F; Fernández M; Carmona F; Ezquerra M
Neurobiol Dis; 2012 Jan; 45(1):462-8. PubMed ID: 21946334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
